Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 31;8(4):632.
doi: 10.3390/vaccines8040632.

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective

Félicien Le Louedec  1 , Fanny Leenhardt  2 , Clémence Marin  3 , Étienne Chatelut  1 , Alexandre Evrard  4 , Joseph Ciccolini  3
Affiliations
Review

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective

Félicien Le Louedec et al. Vaccines (Basel). .

Abstract

Immune check-point inhibitors are drugs that are markedly different from other anticancer drugs because of their indirect mechanisms of antitumoral action and their apparently random effect in terms of efficacy and toxicity. This marked pharmacodynamics variability in patients calls for reconsidering to what extent approved dosing used in clinical practice are optimal or whether they should require efforts for customization in outlier patients. To better understand whether or not dosing could be an actionable item in oncology, in this review, preclinical and clinical development of immune checkpoint inhibitors are described, particularly from the angle of dose finding studies. Other issues in connection with dosing issues are developed, such as the flat dosing alternative, the putative role therapeutic drug monitoring could play, the rise of combinatorial strategies, and pharmaco-economic aspects.

Keywords: checkpoint inhibitors; dosing; pharmacokinetics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sicard G., Fina F., Fanciullino R., Barlesi F., Ciccolini J. Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. Pharmaceutics. 2020;12:758. doi: 10.3390/pharmaceutics12080758. - DOI - PMC - PubMed
    1. Paci A., Veal G., Bardin C., Levêque D., Widmer N., Beijnen J., Astier A., Chatelut E. Review of therapeutic drug monitoring of anticancer drugs part 1—Cytotoxics. Eur. J. Cancer. 2014;50:2010–2019. doi: 10.1016/j.ejca.2014.04.014. - DOI - PubMed
    1. Gao B., Yeap S., Clements A., Balakrishnar B., Wong M., Gurney H. Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. J. Clin. Oncol. 2012;30:4017–4025. doi: 10.1200/JCO.2012.43.5362. - DOI - PubMed
    1. European Medecines Agency Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. [(accessed on 9 September 2020)]; Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-3-r2-n....
    1. Noël A., Jost M., Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin. Cell Dev. Biol. 2008;19:52–60. doi: 10.1016/j.semcdb.2007.05.011. - DOI - PubMed

LinkOut - more resources